To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Everstone Group to invest up to $50 mln in Slayback Pharma
The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma.
